Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prospective Validation of a Points Score System Predicting 30-day Survival
Sponsor: Indiana University
Summary
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin will be assigned to each patient at time of enrollment.
Official title: Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
114
Start Date
2022-09-12
Completion Date
2027-12
Last Updated
2026-01-08
Healthy Volunteers
No
Conditions
Interventions
Point score prediction tool for 30-day survival
This tool requires laboratory data including white blood cell count, neutrophil-lymphocyte ratio, blood urea nitrogen, bilirubin, albumin, lactate dehydrogenase, and red cell distribution, as well as number of attendances to the emergency room in the past 100 days, the site receiving radiation therapy, and the primary cancer type. Each data point correlates with a point value, which are tallied to generate a final score. The scores range from 0-20, with 0 giving the highest chance for survival at 30 days and 20 giving the lowest chance for survival at 30 days
Locations (3)
IU Health West
Avon, Indiana, United States
IU Health North / Schwarz Cancer Center
Carmel, Indiana, United States
Methodist Hospital
Indianapolis, Indiana, United States